Burning Rock Biotech Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yusheng Han
- Full Time Employees
- 674
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- No. 5, Xingdao Ring Road North Guangzhou People's Republic of China 510005
- IPO Date
- Jun 12, 2020
- CIK
- 0001792267
- Website
- brbiotech.com
- Similar Companies
- Business
- Burning Rock Biotech Limited, founded in 2014 and headquartered in Guangzhou, China, develops and provides next-generation sequencing (NGS)-based cancer diagnostics and precision oncology solutions, including therapy selection tests for late-stage cancer patients and early cancer detection technologies; its principal products encompass OncoScreen Plus and OncoScreen IO for pan-cancer tissue profiling, LungPlasma and OncoCompass IO for liquid biopsy companion diagnostics in non-small cell lung cancer, ColonCore for microsatellite instability in gastrointestinal cancers, brPROPHET for preoperative ctDNA detection and postoperative minimal residual disease monitoring, OncoMaster for automated in-hospital NGS analysis, and CanCatch Custom MRD assays for specific tumors such as esophageal squamous cell carcinoma, with clinical applications spanning companion diagnostics for targeted therapy and immunotherapy, tumor diagnosis, recurrence prediction, and susceptibility testing across lung, gastrointestinal, prostate, breast, colorectal, ovarian, pancreatic, bladder, and other cancers. The company operates through three segments—Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services—primarily serving oncologists, hospitals, and biopharmaceutical firms in the People's Republic of China, with additional operations and a CLIA/CAP-certified laboratory in Irvine, California, United States. Recent developments include the September 2025 approval by Japan's Ministry of Health, Labour and Welfare of the OncoGuide OncoScreen Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib; October 2024 NMPA approval of the LungK CDx kit (based on its proprietary 9-gene panel) jointly developed with Dizal Pharmaceutical for sunvozertinib in EGFR exon 20 insertion mutant non-small cell lung cancer; a May 2024 strategic companion diagnostics partnership with Bayer for NGS-based tests supporting its precision oncology portfolio in China; presentation of PROMISE study results and multimodal early detection advancements in September 2025; and a 68.6% year-over-year surge in pharma R&D services revenue to RMB42.0 million in Q3 2025, alongside total revenues of RMB131.6 million reflecting 2.3% growth.
Why These High-Flying Stocks Came Back To Earth
Burning Rock Reports First Quarter 2026 Financial Results
Burning Rock Publishes 2025 Annual Report on Form 20-F
Burning Rock Announces Founder's Purchase of Its ADSs
Burning Rock Biotech (NASDAQ:BNR) versus Safe Pro Group (NASDAQ:SPAI) Head to Head Review
Burning Rock Announces Results of 2025 Annual General Meeting
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
Burning Rock Reports Third Quarter 2025 Financial Results
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
Burning Rock Reports Second Quarter 2025 Financial Results
Burning Rock Reports First Quarter 2025 Financial Results
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
Burning Rock Announces Results of 2024 Annual General Meeting
Burning Rock Reports Third Quarter 2024 Financial Results
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Burning Rock Announces Changes to Management and Board of Directors
Burning Rock Reports Second Quarter 2024 Financial Results
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement